KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC

BACKGROUND: Programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors represent novel therapeutic options for advanced non-small cell lung cancer (NSCLC). However, approximately 50% of patients do not benefit from therapy and experience rapid disease progression. PD-L1 expression is the only...

Descripción completa

Detalles Bibliográficos
Autores principales: Cinausero, Marika, Laprovitera, Noemi, De Maglio, Giovanna, Gerratana, Lorenzo, Riefolo, Mattia, Macerelli, Marianna, Fiorentino, Michelangelo, Porcellini, Elisa, Buoro, Vanessa, Gelsomino, Francesco, Squadrilli, Anna, Fasola, Gianpiero, Negrini, Massimo, Tiseo, Marcello, Ferracin, Manuela, Ardizzoni, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859675/
https://www.ncbi.nlm.nih.gov/pubmed/31798692
http://dx.doi.org/10.1177/1758835919885540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859675/
https://www.ncbi.nlm.nih.gov/pubmed/31798692
http://dx.doi.org/10.1177/1758835919885540

Ejemplares similares